<MedlineCitation Status="Completed">
<MedlineID>10011881</MedlineID>
<PMID>217497</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-8993</ISSN>
<JournalIssue>
<Volume>166</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1979</Year>
<Month>Apr</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Depolarization-induced decreases in fluroescence intensity of gastro-intestinal quinacrine-binding nerves.</ArticleTitle>
<Pagination>
<MedlinePgn>121-37</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Quinacrine, a fluorescent antimalarial acridine derivative, selectively binds to a population of nerve cell bodies and nerve fibers in Auerbach's plexus and elsewhere in the gut. This quinacrine-binding, as measured by fluorescence intensity, is reduced if the nervous elements are depolarized by high K+ (80--150 MM) or veratridine (5 x 10(-5) M) during quinacrine incubation. A reduction of quinacrine-content in nerve terminals is also seen when depolarization (veratridine) takes place for 2 min after quinacrine-incubation, indicating a release of already bound quinacrine. If terminals are depolarized (high K+ or veratridine) before quinacrine incubation, a reduction of quinacrine content is also seen. The depolarization-induced reduction of quinacrine-binding is blocked by Ca2+-removal and, in the case of veratridine by tetrodotoxin. Our findings suggest that quinacrine binds to a compound that is released by nervous activity. Binding mechanism remains to be elucidated. The possibility that quinacrine visualized purine-rich structures is discussed.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Alund</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Olson</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>Brain Res</MedlineTA>
<NlmUniqueID>0045503</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Drug</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>51-41-2</RegistryNumber>
<NameOfSubstance>Norepinephrine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>71-62-5</RegistryNumber>
<NameOfSubstance>Veratridine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-09-7</RegistryNumber>
<NameOfSubstance>Potassium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>83-89-6</RegistryNumber>
<NameOfSubstance>Quinacrine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adrenergic Fibers</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Ileum</DescriptorName>
<QualifierName MajorTopicYN="Y">innervation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Microscopy, Fluorescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Muscle, Smooth</DescriptorName>
<QualifierName>innervation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Myenteric Plexus</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Nerve Fibers</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Norepinephrine</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Potassium</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Quinacrine</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Receptors, Drug</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Synaptic Transmission</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Veratridine</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
